News

Filter

Current filters:

Johnson & Johnson

101 to 110 of 2019 results

NICE consults on draft guidance backing Invokana, as drug debuts in the UK

24-02-2014

UK drugs watchdog the National Institute for Health and Care Excellence is currently appraising Invokana…

DiabetesInvokanaJanssen-CilagJohnson & JohnsonMarkets & MarketingNorthern EuropePharmaceuticalPricingRegulationUK

Another FDA delay for Bayer/J&J’s Xarelto in ACS indication

Another FDA delay for Bayer/J&J’s Xarelto in ACS indication

14-02-2014

There was further negative news for Germany’s Bayer and partner US health care giant Johnson & Johnson,…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationUSAXarelto

Global ulcerative colitis market to reach $6.6 billion by 2022

Global ulcerative colitis market to reach $6.6 billion by 2022

14-02-2014

The global ulcerative colitis market value will increase steadily over the coming years, increasing from…

AbbVieEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeSimponi InjectionTakeda Pharmaceuticals

New Zealand proposal for paliperidone, risperidone and olanzapine depot injections funding

New Zealand proposal for paliperidone, risperidone and olanzapine depot injections funding

14-02-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to fund paliperidone…

Eli LillyHealthcareInvega SustennaJohnson & JohnsonNeurologicalNew ZealandPharmaceuticalPricingRisperdal ConstaZyprexa Relprevv

FDA expands approval of Imbruvica to treat chronic lymphocytic leukemia

FDA expands approval of Imbruvica to treat chronic lymphocytic leukemia

13-02-2014

The US Food and Drug Administration yesterday expanded the approved use of US health care giant Johnson…

ImbruvicaJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulationUSA

Modest growth forecast for global Crohn’s disease market

Modest growth forecast for global Crohn’s disease market

04-02-2014

The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2…

AbbVieBiotechnologyEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeStelara InjectionTakeda Pharmaceuticals

Strong pipeline of MAbs biosimilars in the USA and Europe lends impetus to global market

Strong pipeline of MAbs biosimilars in the USA and Europe lends impetus to global market

30-01-2014

The imminent entry of several companies, including big pharma, small biotech and generic participants,…

BioconBiosimilarsCellTrionDr Reddy's LaboratoriesEuropeHospiraJohnson & JohnsonMarkets & MarketingNorth AmericaRemicadeUSA

Janssen sets up new group targeting unmet global health needs

Janssen sets up new group targeting unmet global health needs

22-01-2014

US health care giant Johnson & Johnson’s Janssen companies are forming Janssen Global Public Health,…

Anti-viralsAntibiotics and Infectious diseasesJanssenJohnson & JohnsonPharmaceuticalResearch

Johnson & Johnson beats expectations, as earnings jump 37%

Johnson & Johnson beats expectations, as earnings jump 37%

22-01-2014

US health care giant Johnson & Johnson reported fourth-quarter and full-year 2013 financials, showing…

FinancialJohnson & JohnsonPharmaceutical

101 to 110 of 2019 results

COMPANY SPOTLIGHT

Menarini

Back to top